Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers

BackgroundChimeric antigen receptor T (CAR-T) cell therapies have achieved remarkable success in the treatment of hematological tumors. However, given the distinct features of solid tumors, particularly heterogeneity, metabolic aggressiveness, and fewer immune cells in tumor microenvironment (TME),...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Lei Tang, Qinyi Sun, Mengyuan Li, Xiaoxiao Yu, Jinguo Meng, Yun Zhang, Yuxiao Ma, Aizhong Zeng, Zhuolan Li, Yuanyuan Liu, Xinyu Xu, Wei Guo
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2024-06-01
Edice:	Frontiers in Immunology
Témata:	CAR-T monoclonal antibodies FcγRI ADCC solid tumors
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1400177/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!